BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 377493)

  • 1. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation.
    Bertelé V; Roncaglioni MC; Donati MB; de Gaetano G
    Thromb Haemost; 1983 Apr; 49(2):81-3. PubMed ID: 6346573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of sulphated polysaccharides on prostacyclin (prostaglandin I2)-induced inhibition of platelet aggregation [proceedings].
    Kindness G; Williamson FB; Long WF
    Biochem Soc Trans; 1980 Jun; 8(3):377-9. PubMed ID: 6995209
    [No Abstract]   [Full Text] [Related]  

  • 5. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of PGI2 infusion during long term extracorporeal circulation with membrane lung in sheep.
    Uziel L; Agostoni A; Pirovano E; Pesenti A; Pelizzola A; Gattinoni L; Galmarini D
    Int J Artif Organs; 1981 May; 4(3):142-5. PubMed ID: 7024139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of heparin on platelet aggregation inhibited by PGI2, trifluoperazine and verapamil.
    Weber DR; Nichols WK; Mohammad SF
    Thromb Res; 1986 May; 42(4):477-87. PubMed ID: 3012821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
    Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
    Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A biphasic effect of prostacyclin (PGI2) on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Thromb Res; 1980 Sep; 19(6):877-81. PubMed ID: 6258262
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparin-mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI2): studies on mechanism.
    Saba SR; Saba HI
    Am J Hematol; 1985 Oct; 20(2):97-105. PubMed ID: 3898823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Pharmacol Res Commun; 1979 Jul; 11(7):605-15. PubMed ID: 388470
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
    Hawiger J; Parkinson S; Timmons S
    Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated plateletes.
    Rao GH; Reddy KR; White JG
    Prostaglandins Med; 1980 Jun; 4(6):385-97. PubMed ID: 6251492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effect of prostaglandins and an aortic proteoglycan on platelet aggregation and plasma clotting.
    Ts'ao C; Eisenstein R
    Prostaglandins Med; 1979 Sep; 3(3):159-66. PubMed ID: 399532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
    Ehrman ML; Jaffe EA
    Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
    Coppe D; Sobel M; Seamans L; Levine F; Salzman E
    J Thorac Cardiovasc Surg; 1981 Feb; 81(2):274-8. PubMed ID: 7005550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostacyclin can replace heparin in haemodialysis in dogs.
    Woods HF; Ash G; Weston MJ; Bunting S; Moncada S; Vane JR
    Lancet; 1978 Nov; 2(8099):1075-7. PubMed ID: 82090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PGI2 on the inactivation of thrombin, factor Xa, and plasmin by antithrombin-III and heparin.
    Blaskó G
    Prostaglandins; 1979 Jul; 18(1):3-9. PubMed ID: 160589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.